日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions

结直肠癌靶向治疗的进展：克服挑战，探索未来方向

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17172810
Khelwatty, Said A; Puvanenthiran, Soozana; Seddon, Alan M; Bagwan, Izhar; Essapen, Sharadah; Modjtahedi, Helmout
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

一线治疗上皮性卵巢癌、输卵管癌或原发性腹膜癌的每周高剂量化疗（ICON8）：一项开放标签、随机、对照的3期试验的总生存期结果

期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(22)00283-2
Clamp, Andrew R; James, Elizabeth C; McNeish, Iain A; Dean, Andrew; Kim, Jae-Won; O'Donnell, Dearbhaile M; Gallardo-Rincon, Dolores; Blagden, Sarah; Brenton, James; Perren, Tim J; Sundar, Sudha; Lord, Rosemary; Dark, Graham; Hall, Marcia; Banerjee, Susana; Glasspool, Rosalind M; Hanna, C Louise; Williams, Sarah; Scatchard, Kate M; Nam, Helena; Essapen, Sharadah; Parkinson, Christine; McAvan, Lucy; Swart, Ann Marie; Popoola, Babasola; Schiavone, Francesca; Badrock, Jonathan; Fananapazir, Fuad; Cook, Adrian D; Parmar, Mahesh; Kaplan, Richard; Ledermann, Jonathan A
肿瘤
肿瘤免疫
卵巢癌
发表日期：2022
文献求助 收藏

Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

一线新辅助卡铂-紫杉醇方案治疗卵巢癌、输卵管癌或原发性腹膜癌的客观疗效（ICON8）：一项随机3期试验的事后探索性分析

期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(20)30591-X
Morgan, Robert D; McNeish, Iain A; Cook, Adrian D; James, Elizabeth C; Lord, Rosemary; Dark, Graham; Glasspool, Rosalind M; Krell, Jonathan; Parkinson, Christine; Poole, Christopher J; Hall, Marcia; Gallardo-Rincón, Dolores; Lockley, Michelle; Essapen, Sharadah; Summers, Jeff; Anand, Anjana; Zachariah, Abel; Williams, Sarah; Jones, Rachel; Scatchard, Kate; Walther, Axel; Kim, Jae-Weon; Sundar, Sudha; Jayson, Gordon C; Ledermann, Jonathan A; Clamp, Andrew R
肿瘤
肿瘤免疫
卵巢癌
发表日期：2021
文献求助 收藏

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

HER2表达可预测接受西妥昔单抗治疗的RAS野生型转移性结直肠癌患者的生存期

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers13040638
Khelwatty, Said A; Puvanenthiran, Soozana; Essapen, Sharadah; Bagwan, Izhar; Seddon, Alan M; Modjtahedi, Helmout
肿瘤
肠癌
肿瘤免疫
HER2
RAS
发表日期：2021
文献求助 收藏

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer-A Single UK Centre Experience

三氟尿苷/替吡嘧啶治疗转移性结直肠癌的长期真实世界疗效——英国单中心经验

期刊:Current Oncology
影响因子:3.4
doi:10.3390/curroncol28030208
Tong, Daniel; Wang, Lei; Mendis, Jeewaka; Essapen, Sharadah
肿瘤
肠癌
肿瘤免疫
发表日期：2021
文献求助 收藏

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer

假定 CSC 标志物 CD44、CD133、野生型 EGFR 和 EGFRvIII 在转移性结直肠癌中的共表达及预后意义

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.26722
Said Abdullah Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan M Seddon, Helmout Modjtahedi
肿瘤
肠癌
FCM
ICC
WB
PROM1
发表日期：2019
文献求助 收藏

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

结直肠癌辅助奥沙利铂-氟尿嘧啶联合化疗3个月与6个月疗效比较（SCOT）：一项国际性、随机、3期非劣效性试验

期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(18)30093-7
Iveson, Timothy J; Kerr, Rachel S; Saunders, Mark P; Cassidy, Jim; Hollander, Niels Henrik; Tabernero, Josep; Haydon, Andrew; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; McQueen, John; Scudder, Claire; Boyd, Kathleen Anne; Briggs, Andrew; Waterston, Ashita; Medley, Louise; Wilson, Charles; Ellis, Richard; Essapen, Sharadah; Dhadda, Amandeep S; Harrison, Mark; Falk, Stephen; Raouf, Sherif; Rees, Charlotte; Olesen, Rene K; Propper, David; Bridgewater, John; Azzabi, Ashraf; Farrugia, David; Webb, Andrew; Cunningham, David; Hickish, Tamas; Weaver, Andrew; Gollins, Simon; Wasan, Harpreet S; Paul, James
肠癌
肿瘤免疫
肿瘤
发表日期：2018
文献求助 收藏

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer

HER家族成员、EGFRvIII、c-MET、CD44在卵巢癌患者中的共表达及其预后意义

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.24791
Puvanenthiran, Soozana; Essapen, Sharadah; Haagsma, Ben; Bagwan, Izhar; Green, Margaret; Khelwatty, Said Abdullah; Seddon, Alan; Modjtahedi, Helmout
EGFR
肿瘤
EGF
卵巢癌
CD4
MET
肿瘤免疫
CD44
T细胞
发表日期：2018
文献求助 收藏

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer

免疫组织化学检测野生型 EGFR 及其配体的共表达对转移性结直肠癌患者西妥昔单抗治疗反应的影响

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.13835
Said Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan Seddon, Helmout Modjtahedi
肿瘤
肠癌
发表日期：2017
文献求助 收藏

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs

推定的癌症干细胞标志物和生长因子受体表达对卵巢癌细胞对各种形式的小分子酪氨酸激酶抑制剂和细胞毒药物治疗敏感性的影响

期刊:International Journal of Oncology
影响因子:4.5
doi:10.3892/ijo.2016.3678
Soozana Puvanenthiran, Sharadah Essapen, Alan M Seddon, Helmout Modjtahedi
发育与干细胞
肿瘤
卵巢癌
干细胞
发表日期：2016
文献求助 收藏